CompletedPhase 4

Povidone-Iodine for Nasal Decolonization

United States192 participantsStarted 2022-09-06

Plain-language summary

To evaluate the efficacy and tolerability of 10% povidone-iodine in eliminating nasal carriage of Staphylococcus aureus and MRSA. To determine whether a more convenient, single-dose, pre-operative 10% povidone-iodine (PI) application is effective in reducing nasal carriage of S. aureus and MRSA. We expect a statistically significant decrease in S. aureus/MRSA colonization in nasal cultures taken perioperatively after intervention in patients who received pretreatment with PI as compared to patients who received normal saline (NS).

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * community-based patients ages 18-80 * American Society of Anesthesiology (ASA) 1-3 * undergoing an outpatient surgery for at least 1 hour and up to 6 hours duration Exclusion Criteria: * pregnancy * allergy to povidone-iodine * infectious indication for surgery or preexisting known infection/wound * immunocompromised state * use of chemotherapy or steroids within 30 days prior to surgery * use of antimicrobial therapy within 30 days prior to surgery * surgeries where field avoidance prevents intraoperative access to the nares

What they're measuring

Change in S. Aureus/MRSA Colony Forming Units (CFU) in Nasal Swab Specimen After Treatment in Patients Who Presented With a Positive for S. Aureus/MRSA Pre-interventional Nasal Swab Specimen.

Timeframe: 1, 2, and 3 hours after application of Povidone-Iodine or saline solution

Trial details

NCT IDNCT05529173

SponsorRutgers, The State University of New Jersey

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-13

Results submitted2024-08-28

View on ClinicalTrials.gov More Surgical Wound Infection trials